Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China

Abstract

Objective This survey aims to explore the current medical treatment of major depressive disorder (MDD) in China and match its degree with Canadian Network for Mood and Anxiety Treatments (CANMAT). Methods A total of 3275 patients were recruited from 16 mental health centers and 16 general hospitals in China. Descriptive statistics presented the total number and percentage of drugs, as well as all kinds of treatments. Results Selective serotonin reuptake inhibitors (SSRIs) accounted for the largest proportion (57.2%), followed by serotonin-noradrenaline reuptake inhibitors (SNRIs) (22.8%) and mirtazapine (7.0%) in the first therapy, while that of SNRIs (53.9%) followed by SSRIs (39.2%) and mirtazapine (9.8%) in the follow-up therapy. An average of 1.85 medications was administered to each MDD patient. Conclusion SSRIs were the first choice in the first therapy, while the proportion of those drugs decreased during the follow-up therapy and were replaced by SNRIs. Plenty of combined pharmacotherapies were directly selected as the first trial of patients, which was inconsistent with guideline recommendations.

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models

“…It is known for its various beneficial effects, including relaxing the liver and alleviating depression, as well as clearing heat and dampness. Additionally, it has properties that can reduce swelling and relieve pain[ 62 ]. Sadeghi et al [ 63 ] reported that when comparing the two treatments' effects on patients with mild and moderate depression, they discovered that Hypericum perforatum was more effective than antidepressants.…”

Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?

“…Although monoaminergic antidepressants have been under development for half of a century, there is no strong evidence of sequenced treatment alternatives for implementing pharmacological strategies (monotherapy, combination, polypharmaceutical or augmentation strategies) [ 5 ], as well as the effectiveness between any treatments at any treatment level [ 6 ]. Moreover, there is no significant difference between the different psychopharmacological classes used as augmenters in terms of symptom severity and treatment response [ 7 ].…”